ArticleAntioxidants (Basel, Switzerland)2026
Anti-Tumor Activity of Stevia Leaf Extract Fermented by the Plant-Derived
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is a highly aggressive malignancy with a poor prognosis and limited efficacy of conventional therapies. Developing safe and effective natural adjuvant therapies is therefore of considerable interest. This study evaluated the in vivo anti-tumor activity of stevia leaf extract fermented by
methodsMice with PANC-1 tumors were randomly assigned to four groups: normal saline (NC group), unfermented stevia leaf extract (SLE, Unfer group), fermented stevia leaf extract by
resultsFermented stevia leaf extract significantly inhibited tumor growth, as evidenced by reduced tumor volume and weight. Serum pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) were markedly decreased, accompanied by improvement in liver injury markers (ALT, AST) and lactate dehydrogenase (LDH). In tumor tissues, FSLE was associated with increased protein expression of cleaved caspase-3 and Bax, along with decreased Bcl-2 levels. Notably, Nrf2 protein expression in tumor tissues was downregulated, while intratumoral IL-6 levels were also decreased. In the liver, treatment was accompanied by increased Nrf2 and HO-1 mRNA expression, enhanced superoxide dismutase (SOD) activity, and reduced malondialdehyde (MDA) levels.
conclusionsFSLE exerts anti-tumor effects in a PANC-1 xenograft model that are associated with the modulation of inflammation, oxidative stress, and apoptosis-related pathways. These observations provide experimental and theoretical support for the further development of fermented plant-derived products as adjunctive therapies for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.